N/A N=127 Infectious Pathogens in Acute Respiratory Illness in Adults and Elderly
Respiratory Disorders
Primary: Mean Estimated Number of Acute Exacerbation of COPD (AECOPD) — 3.04 AECOPD/subject/year
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=43 Association Between Increased Oxidative Stress, Anti-Inflammatory Fatty Acid Formation, and Airway Infection in People With Asthma and Chronic Obstructive Pulmonary Disease
Asthma · Pulmonary Disease, Chronic Obstructive
Primary: 8-isoprostane Levels as Biochemical Markers for Nonenzymatic Oxidative Stress in Asthma — 292.4; 421.8 pg/ml
Phase 1 N=14 Does Pulmonary Rehabilitation Improve Balance in People With Respiratory Disease?
Lung Diseases
Primary: Standing Balance - Sway Path — 1.57; 3.40; 1.65; 2.59 cm/s
Phase 2 N=98 Human Lung Responses to Respiratory Pathogens
Respiratory Infection
Primary: Antimicrobial Activity by Airway Surface Liquid (ASL) as Measured by Relative Light Units (RLU) — -581; -485 Relative Light Units (RLU)
N/A N=1,333 Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
Pulmonary Arterial Hypertension
Primary: Prevalence of Respiratory Tract-Related Adverse Events of Interest — 52; 51; 16; 14 percentage of participants
N/A N=2,862 The Respiratory Protection Effectiveness Clinical Trial
Influenza · Respiratory Syncytial Viruses · Paramyxoviridae Infections
Primary: Protective Effects of N95 Respirators vs Medical Masks (MM) as Assessed by Number of Influenza A and B Events — 222; 204 number of influenza A and B events
N/A N=21 Effectiveness of Respiratory Physiotherapy in Children With Neuromuscular Disease
Neuromuscular Diseases
Primary: Change From Baseline Vital Capacity at One Year. — 33.33; -7.41 percentage of Change of vital capacity — p=<0.001
Phase 3 N=122 GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs) — 120; 27 Participants
Phase 3 N=42 Expiratory Muscle Training for Persons With Neurodegenerative Disease
Parkinson's Disease · Multiple Sclerosis
Primary: Maximum Expiratory Pressure (MEP) — 78.6; 75.56; 99.00; 99.38 cm H2O — p=0.899
N/A N=25 Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients
Idiopathic Pulmonary Fibrosis
Primary: 6 Minute Walk Distance — -6.2; -15.3 meters
N/A N=50 Effects of Deployment Exposures on Cardiopulmonary and Autonomic Function
Abnormality, Respiratory System · Autonomic Nervous System
Primary: FEV1 — 0.94; 1.08; 0.95; 1.09 percentage of predicted normal values
N/A N=60 Health Effects of Diesel Exhaust in Asthmatic Patients: A Real-world Study in a London Street
Asthma
Primary: Spirometry, Percentage Change in FEV1 From Baseline — -1.0; -4.8; -2.2; -7.4 percentage change in FEV1 from baseline — p=<0.05
N/A N=12 High-Intensity Interval Training to Improve Symptoms of Deployment-Related Respiratory Disease
Occupational Exposure
Primary: Maximum Oxygen Consumption (VO2max) — 26.4 ml/kg/min
N/A N=14 Effect of Respiratory Exerciser on Pulmonary Functions of COVID-19 Patients
Covid19 · Respiratory Function Loss · Coronavirus Infection
Primary: Change in Peak Expiratory Flow (Absolute Value) — 175; 160 ml/min — p=0.374
N/A N=24 The Effects of Respiratory Training on Voice
Muscle Tension Dysphonia
Primary: Post Training Lung Volume Initiation — 21.07; 27.04 % vital capacity relative to rest level — p=<0.0005
N/A N=9 Residential Cleaning of Indoor Air to Protect COPD Patients
Chronic Obstructive Pulmonary Disease
Primary: Mean Change in St. George Respiratory Questionnaire — -12.5; -0.45 score on a scale
N/A N=22 Non-invasive Ventilation System in Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive · Airflow Obstruction, Chronic · Chronic Obstructive Airway Disease
Primary: Device Tidal Volume — 180 mL
N/A N=523 Wood Stove Interventions and Child Respiratory Health
Lower Tract Respiratory Infection
Primary: Number of Participants With at Least One LRTI During Follow-up Period — 16; 20; 17; 138 Participants — p=0.68
N/A N=60 Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program
Lung Diseases · Medication Compliance
Primary: Forced Oscillation Technique (FOT) Measures — 4.4; 3.7; 1.0; 0.6 resonant frequency
Phase 4 N=63 Maintain Respiratory Muscle Function and Reduce Pneumonia Risk in Cancer Patients
Cancer
Primary: Sniff Nasal Inspiratory Pressure (SNIP) — 90; 87; 89; 109 cmH20
N/A N=34 The NIH Exercise Therapy for Advanced Lung Disease Trials: Response and Adaptation to Aerobic Exercise in Patients With Interstitial Lung Disease
Interstitial Lung Disease · Idiopathic Pulmonary Fibrosis · Interstitial Pneumonitis
Primary: Change in 6-minute Walk Test Distance (6MWD) — 46.5; 23.2 Meters
N/A N=270 Comparison of Classification Standards of Bronchopulmonary Dysplasia (BPD) in Premature Infants
Bronchopulmonary Dysplasia
Primary: Respiratory Adverse Outcomes — 27; 60 Participants
N/A N=125 Families-At-risk for Interstitial Lung Disease Study
Interstitial Lung Disease · Idiopathic Pulmonary Fibrosis
Primary: Number of Participants With ILA (Interstitial Lung Abnormalities) — 85; 13 Participants
N/A N=197 Occurrence of Potential Bacterial and Viral Pathogens in Stable Chronic Obstructive Pulmonary Disease and During Acute Exacerbations of the Disease, in Asia Pacific
Respiratory Disorders
Primary: Percentage of Sputum Samples Positive for Bacterial Pathogens as Identified by Bacteriological Methods, in Any Stable COPD Patients and During AECOPDs — 74.2; 78; 94.6…
N/A N=27 Doxycycline for COPD in HIV-Infected Patients
HIV · Chronic Obstructive Pulmonary Disease (COPD) · Emphysema
Primary: Safety of Doxycycline, as Measured by the Number of Subjects With Any Treatment-related Adverse Events. — 3; 1 Participants
N/A N=252 Chronic Obstructive Pulmonary Disease (COPD) Biomarker Identification Study
COPD
Primary: Spirometry Measurement: Percentage of Predicted Forced Expiratory Volume in 1 Second (FEV1 %Pred) — 75.572; 100.837; 108.311; 111.849 percent of predicted FEV1 — p=<0.0001
Phase 2 N=44 Respiratory Kinematics of Cough in Healthy Older Adults and Parkinson's Disease
Cough · Parkinson's Disease
Primary: Peak Expiratory Flow Rate — 4.34; 3.92 Liters of air/second
N/A N=25 Respiratory Strength Training in Cardiac Surgical Patients
Cardiovascular Diseases · Thoracic Diseases · Surgery
Primary: Adherence to Respiratory Strength Training — 35750 Repetitions
N/A N=26 Respiratory Impedance and Obliterative Bronchiolitis
Hematopoietic Stem Cell Transplantation · Obliterative Bronchiolitis
Primary: Airway Distensibility With Lung Inflation After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) — 0.07 1/cmH2O*s
N/A N=13 Evaluation of Respiratory Heast Loss as a Physiologic Patient Monitor for Acute Care Medicine
Respiratory Heat Loss
Primary: Evaluation of Respiratory Heat Loss as a Physiologic Patient Monitor for Acute Care Medicine — 29.7 Joules per minute